- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: Global Sales to Hit US$57 Billion by 2026
A new research report shows just how much global cannabis sales numbers are expected to grow by 2026.
Business research firm BDSA has issued new projections for global cannabis sales in the next few years.
Meanwhile, a new strategic partnership will see one of the biggest cannabis brands make its way over to the European market.
Keep reading to find out more cannabis highlights from the past five days.
New data paints clear picture of global cannabis sales
BDSA's new data reveals a positive outlook for long-term cannabis sales growth. After coming in at US$30 billion in 2021, global sales are expected to hit US$57 billion by 2026, increasing at a compound annual growth rate of 13 percent.
As far as 2022 goes, in the US, legal cannabis sales are expected to bring in US$27 billion. BDSA predicts that the US market will account for 75 percent of total global cannabis sales by 2026.
Roy Bingham, CEO of BDSA, said the market is now past the “hockey stick” trend of sales growth.
“Still, our updated forecast predicts that steady gains in developing US markets will continue to drive single-digit annual growth in total US legal sales in 2022, with continued growth prospects out to 2026,” he said.
The firm's data shows that sales numbers have plateaued in some of the more mature state markets, like California and Colorado.
But while these states have seen dwindling sales, other states opening their doors to cannabis are expected to bring in some serious numbers. Illinois alone is seen producing US$2 billion in 2022, according to the data.
In terms of competition from other nations, BDSA believes Germany and Mexico could throw off America's dominance in cannabis sales.
Most recognizable cannabis brand expands to Europe
Cookies confirmed it will make its way to Portugal by way of a new licensing agreement with Akanda (NASDAQ:AKAN).
“The partners we chose in Portugal have one of the most advanced facilities I’ve seen and will be producing some of the best cannabis in the world,” Cookies CEO Gilbert Milam, known as Berner, said.
Cookies products will be produced in Portugal through Akanda’s acquisition asset Holigen.
Akanda CEO Tej Virk praised the agreement and credited the brand recognition brought forth by Cookies.
“Cookies premium genetics are an essential pillar to have in our portfolio as these markets begin to open up,” Virk said, referring to the current wave of legalization efforts throughout Europe, but particularly in Germany.
Cannabis company news
- High Tide (NASDAQ:HITI,TSXV:HITI)reported financial results for its third fiscal quarter, indicating revenue of C$95.4 million, an 18 percent uptick compared to the previous quarter. However, the firm reported a net loss of C$2.7 million.
- Innovative Industrial Properties (NYSE:IIPR)declared its Q3 dividend for shareholders. The firm will be granting a US$1.80 per share dividend.
- Avicanna (TSX:AVCN,OTCQX:AVCNF)expanded its research relationship with the University of Toronto for the investigation of cannabinoid-based products in the field of epilepsy. “The cannabinoids, alone and in combination, are some of the most promising antiseizure drugs that I have seen in many years of research,” said Dr. Mac Burnham, the university's lead for cannabis research.
Don't forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
- How to Invest in a Cannabis Stock ›
- Why Consider Investing in the Cannabis Industry? | INN ›
- Ways to Invest in Cannabis ›
- 3 Cannabis Investing Experts Explain US Legalization Hype ›
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.